Nicholas G Zaorsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4756761/publications.pdf

Version: 2024-02-01

76326 91884 6,162 177 40 69 citations h-index g-index papers 179 179 179 8173 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A population-based study of cardiovascular disease mortality risk in US cancer patients. European Heart Journal, 2019, 40, 3889-3897.	2.2	501
2	Causes of death among cancer patients. Annals of Oncology, 2017, 28, 400-407.	1.2	415
3	Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiotherapy and Oncology, 2019, 130, 104-112.	0.6	189
4	Suicide among cancer patients. Nature Communications, 2019, 10, 207.	12.8	177
5	Single versus Multifraction Stereotactic Radiosurgery for Large Brain Metastases: An International Meta-analysis of 24 Trials. International Journal of Radiation Oncology Biology Physics, 2019, 103, 618-630.	0.8	168
6	Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncology, The, 2015, 16, e510-e521.	10.7	160
7	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 659-665.	1.2	149
8	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	1.9	140
9	Stroke among cancer patients. Nature Communications, 2019, 10, 5172.	12.8	125
10	Fatal heart disease among cancer patients. Nature Communications, 2020, 11, 2011.	12.8	124
11	Epidemiology of liver metastases. Cancer Epidemiology, 2020, 67, 101760.	1.9	120
12	Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer. JAMA Oncology, 2021, 7, 92.	7.1	114
13	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	3.8	106
14	What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiotherapy and Oncology, 2015, 115, 295-300.	0.6	102
15	Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. European Urology Oncology, 2019, 2, 515-523.	5 . 4	97
16	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2022, 40, 2957-2995.	1.6	97
17	Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015. JAMA Network Open, 2020, 3, e2027738.	5.9	91
18	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus, 2019, 5, 958-969.	3.1	86

#	Article	IF	CITATIONS
19	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. Journal of Thoracic Oncology, 2018, 13, 510-520.	1.1	77
20	Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancerÂ(CRiSP): An international systematic review and metaâ€analysis. Cancer, 2020, 126, 2120-2131.	4.1	72
21	MicroRNA expression altered by diet: Can food be medicinal?. Ageing Research Reviews, 2014, 17, 16-24.	10.9	68
22	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316.	10.7	68
23	Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. Cancer Letters, 2016, 375, 349-359.	7.2	67
24	Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. JAMA Oncology, 2020, 6, 1881.	7.1	66
25	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Radiotherapy and Oncology, 2020, 151, 141-148.	0.6	62
26	Evolution of advanced technologies in prostate cancer radiotherapy. Nature Reviews Urology, 2013, 10, 565-579.	3.8	61
27	Pericytes: a double-edged sword in cancer therapy. Future Oncology, 2015, 11, 169-179.	2.4	61
28	Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget, 2016, 7, 57391-57413.	1.8	61
29	Epidemiology of bone metastases. Bone, 2022, 158, 115783.	2.9	61
30	High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treatment Reviews, 2014, 40, 414-425.	7.7	57
31	Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo. Cancer Letters, 2015, 356, 985-993.	7.2	57
32	Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treatment Reviews, 2013, 39, 728-736.	7.7	56
33	Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiotherapy and Oncology, 2013, 106, 317-322.	0.6	55
34	ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK. Molecular Cancer Therapeutics, 2013, 12, 696-704.	4.1	55
35	Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treatment Reviews, 2016, 48, 50-60.	7.7	53
36	What Are Medical Students in the United States Learning About Radiation Oncology? Results of a Multi-Institutional Survey. International Journal of Radiation Oncology Biology Physics, 2016, 94, 235-242.	0.8	53

#	Article	IF	Citations
37	Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 409-415.	1.3	52
38	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
39	Prehabilitation exercise therapy for cancer: A systematic review and metaâ€analysis. Cancer Medicine, 2021, 10, 4195-4205.	2.8	48
40	Splenic irradiation for splenomegaly: A systematic review. Cancer Treatment Reviews, 2017, 53, 47-52.	7.7	45
41	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. International Journal of Molecular Sciences, 2018, 19, 3054.	4.1	44
42	Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. Clinical Genitourinary Cancer, 2017, 15, 326-335.e3.	1.9	43
43	Publication Productivity and Academic Rank in Medicine: A Systematic Review and Meta-Analysis. Academic Medicine, 2020, 95, 1274-1282.	1.6	43
44	Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis. Radiotherapy and Oncology, 2017, 125, 13-20.	0.6	42
45	Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. Radiotherapy and Oncology, 2020, 144, 165-179.	0.6	42
46	Epidemiology of synchronous brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa041.	0.7	42
47	Impact of obesity on outcomes after definitive doseâ€escalated intensityâ€modulated radiotherapy for localized prostate cancer. Cancer, 2015, 121, 3010-3017.	4.1	40
48	The role of radiation therapy in the management of sialorrhea: A systematic review. Laryngoscope, 2016, 126, 80-85.	2.0	39
49	Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, e13-e17.	0.8	37
50	De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials. Oral Oncology, 2020, 103, 104608.	1.5	37
51	A systematic review and meta-analysis of the prognostic value of radiomics based models in non-small cell lung cancer treated with curative radiotherapy. Radiotherapy and Oncology, 2021, 155, 188-203.	0.6	37
52	Sex Differences in Academic Productivity Across Academic Ranks and Specialties in Academic Medicine. JAMA Network Open, 2021, 4, e2112404.	5.9	37
53	The Dilemma of a Rising Prostate-Specific Antigen Level After Local Therapy: What Are Our Options?. Seminars in Oncology, 2013, 40, 322-336.	2.2	36
54	Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?. Cancer Treatment Reviews, 2013, 39, 212-218.	7.7	36

#	Article	IF	CITATIONS
55	Skin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis. Radiotherapy and Oncology, 2018, 126, 386-393.	0.6	35
56	Google Search Trends in Oncology and the Impact of Celebrity Cancer Awareness. Cureus, 2019, 11, e5360.	0.5	35
57	Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis InÂVitro and InÂVivo. International Journal of Radiation Oncology Biology Physics, 2018, 101, 49-62.	0.8	33
58	Single fraction radiosurgery, fractionated radiosurgery, and conventional radiotherapy for spinal oligometastasis (SAFFRON): A systematic review and meta-analysis. Radiotherapy and Oncology, 2020, 146, 76-89.	0.6	33
59	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy and Oncology, 2020, 148, 235-242.	0.6	33
60	Clinical Trial Accrual at Initial Course of Therapy for Cancer and Its Impact on Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1309-1316.	4.9	33
61	Surgical excision, Mohs micrographic surgery, externalâ€beam radiotherapy, or brachytherapy for indolent skin cancer: An international metaâ€analysis of 58 studies with 21,000 patients. Cancer, 2019, 125, 3582-3594.	4.1	31
62	ACR Appropriateness Criteria \hat{A}^{\otimes} external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Advances in Radiation Oncology, 2017, 2, 62-84.	1.2	30
63	Assessing the Value of an Optional Radiation Oncology Clinical Rotation During the Core Clerkships in Medical School. International Journal of Radiation Oncology Biology Physics, 2012, 83, e465-e469.	0.8	28
64	The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nature Reviews Urology, 2012, 9, 258-265.	3.8	27
65	MicroRNA-223 Enhances Radiation Sensitivity of U87MG Cells InÂVitro and InÂVivo by Targeting Ataxia Telangiectasia Mutated. International Journal of Radiation Oncology Biology Physics, 2014, 88, 955-960.	0.8	27
66	Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget, 2015, 6, 15690-15703.	1.8	27
67	Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 46-55.	1.3	26
68	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	3.8	26
69	Assessment of the American Joint Committee on Cancer Staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network riskâ€stratification method. Cancer, 2012, 118, 5535-5543.	4.1	25
70	Riskâ€adapted stereotactic body radiation therapy for central and ultraâ€central earlyâ€stage inoperable nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3553-3564.	3.9	25
71	Dose–response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiotherapy and Oncology, 2021, 154, 207-213.	0.6	24
72	Toxicity after radiotherapy in patients with historically accepted contraindications to treatment (CONTRAD): An international systematic review and meta-analysis. Radiotherapy and Oncology, 2019, 135, 147-152.	0.6	23

#	Article	IF	CITATIONS
73	Longâ€term causes of death among pediatric patients with cancer. Cancer, 2020, 126, 3102-3113.	4.1	23
74	Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. Journal of Thoracic Disease, 2014, 6, 387-98.	1.4	23
75	Multimodality Therapy for Patients With High-Risk Prostate Cancer: Current Status and Future Directions. Seminars in Oncology, 2013, 40, 308-321.	2.2	22
76	A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer. Research and Reports in Urology, 2016, Volume 8, 145-158.	1.0	22
77	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Advances in Radiation Oncology, 2017, 2, 437-454.	1.2	21
78	Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. Oncotarget, 2016, 7, 18135-18145.	1.8	21
79	A Patient-Level Data Meta-analysis of the Abscopal Effect. Advances in Radiation Oncology, 2022, 7, 100909.	1.2	20
80	Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2020, 6, 404-418.	3.1	19
81	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiotherapy and Oncology, 2020, 151, 26-32.	0.6	19
82	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 26-32.	1.2	19
83	Panâ€cancer analysis of prognostic metastatic phenotypes. International Journal of Cancer, 2022, 150, 132-141.	5.1	19
84	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	1.9	19
85	A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncology, 2014, 10, 457-474.	2.4	18
86	Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2021, 111, 371-384.	0.8	18
87	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
88	Differentiating Lymphovascular Invasion from Retraction Artifact on Histological Specimen of Breast Carcinoma and Their Implications on Prognosis. Journal of Breast Cancer, 2012, 15, 478.	1.9	17
89	Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in highâ€risk extremity/trunk softâ€tissue sarcoma?. Cancer, 2019, 125, 3801-3809.	4.1	17
90	The Epidemiology of Lung Metastases. Frontiers in Medicine, 2021, 8, 723396.	2.6	17

#	Article	IF	CITATIONS
91	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 572-579.	1.3	15
92	Patient reported outcomes among treatment modalities for prostate cancer. Canadian Journal of Urology, 2016, 23, 8535-8545.	0.0	15
93	Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?. Expert Review of Anticancer Therapy, 2014, 14, 39-50.	2.4	14
94	Chondrosarcoma of the hyoid bone: Case report and review of current management options. Head and Neck, 2014, 36, E65-72.	2.0	14
95	Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. Prostate, 2017, 77, 1160-1166.	2.3	14
96	Reducing the Toxicity of Radiotherapy for Pancreatic Cancer With Magnetic Resonance-guided Radiotherapy. Toxicological Sciences, 2020, 175, 19-23.	3.1	14
97	Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies. JNCI Cancer Spectrum, 2021, 5, pkab050.	2.9	14
98	Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncology, 2012, 8, 37-54.	2.4	13
99	Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma. OncoTargets and Therapy, 2015, 8, 437.	2.0	13
100	Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1112-1120.	1.1	13
101	Industry Funding Among Leadership in Medical Oncology and Radiation Oncology in 2015. International Journal of Radiation Oncology Biology Physics, 2017, 99, 280-285.	0.8	13
102	Survival after palliative radiation therapy for cancer: The METSSS model. Radiotherapy and Oncology, 2021, 158, 104-111.	0.6	13
103	Optimizing patient positioning for intensity modulated radiation therapy in hippocampal-sparing whole brain radiation therapy. Practical Radiation Oncology, 2014, 4, 378-383.	2.1	12
104	Exercise Therapy and Radiation Therapy for Cancer: A Systematic Review. International Journal of Radiation Oncology Biology Physics, 2021, 110, 973-983.	0.8	12
105	Medical Service Use and Charges for Cancer Care in 2018 for Privately Insured Patients Younger Than 65 Years in the US. JAMA Network Open, 2021, 4, e2127784.	5.9	12
106	Current treatment and future directions in the management of anal cancer. Ca-A Cancer Journal for Clinicians, 2022, 72, 183-195.	329.8	12
107	Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2022, 86, 1246-1257.	1.2	12
108	Impact of a Radiation Oncology Elective on the Careers of Young Physicians: Update on a Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics, 2013, 86, 214-215.	0.8	11

#	Article	IF	CITATIONS
109	Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 116-121.	1.8	11
110	Industry Funding Is Correlated With Publication Productivity of US Academic Radiation Oncologists. Journal of the American College of Radiology, 2019, 16, 244-251.	1.8	11
111	Impact of radiation therapy facility volume on survival in patients with cancer. Cancer, 2021, 127, 4081-4090.	4.1	10
112	Impact of Facility Surgical Volume on Survival in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 495-503.	4.9	10
113	Adult nodular lymphocyteâ€predominant Hodgkin lymphoma: treatment modality utilization and survival. Cancer Medicine, 2018, 7, 1118-1126.	2.8	9
114	Total skin electron beam therapy in mycosis fungoides—a shift towards lower dose?. Chinese Clinical Oncology, 2019, 8, 9-9.	1.2	9
115	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro. American Journal of Cancer Research, 2014, 4, 943-51.	1.4	9
116	Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Review of Medical Devices, 2013, 10, 751-763.	2.8	8
117	Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. Brachytherapy, 2015, 14, 316-321.	0.5	8
118	Is robotic arm stereotactic body radiation therapy â€~virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data. Expert Review of Medical Devices, 2015, 12, 317-327.	2.8	8
119	Importance of Surgical Margin Status in Ductal Carcinoma In Situ. Clinical Breast Cancer, 2016, 16, 312-318.	2.4	8
120	The Influence of Online Forums on Radiation Oncology Residency Program Selection. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1009-1011.	0.8	8
121	Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry. Cancer Medicine, 2020, 9, 3623-3633.	2.8	8
122	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	8
123	A Case of Classic Raymond Syndrome. Case Reports in Neurological Medicine, 2012, 2012, 1-3.	0.4	7
124	The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 321-326.	1.3	7
125	Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. Cancer Biology and Therapy, 2013, 14, 883-887.	3.4	6
126	Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy, 2014, 13, 456-464.	0.5	6

#	Article	IF	CITATIONS
127	Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 404-411.	1.2	6
128	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
129	The Responsibilities of a Chief Resident in Radiation Oncology: Results of a National Survey. International Journal of Radiation Oncology Biology Physics, 2013, 87, 460-461.	0.8	5
130	ASTRO APEx®and RO-ILSâ,,¢ are applicable to medical malpractice in radiation oncology. Future Oncology, 2016, 12, 2643-2657.	2.4	5
131	Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancer. Oncotarget, 2017, 8, 62998-63013.	1.8	5
132	Long-Term Risk of Death From Heart Disease Among Breast Cancer Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 784409.	2.4	5
133	Exposure to radon and heavy particulate pollution and incidence of brain tumors. Neuro-Oncology, 2023, 25, 407-417.	1.2	5
134	Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines, 2018, 6, 7.	3.2	4
135	Retrospective comparative effectiveness research: will changing the analytical methods change the results?. International Journal of Cancer, 2022, , .	5.1	4
136	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 278-289.	0.8	4
137	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e1-848.e7.	1.6	3
138	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]. European Urology Focus, 2021, 7, 404-405.	3.1	3
139	A systematic review of home-based dietary interventions during radiation therapy for cancer. Technical Innovations and Patient Support in Radiation Oncology, 2020, 16, 10-16.	1.9	3
140	Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?. International Journal of Radiation Oncology Biology Physics, 2021, 111, 965-967.	0.8	3
141	Non-adherence to multi-modality cancer treatment guidelines in the United States. Advances in Radiation Oncology, 2022, 7, 100938.	1.2	3
142	Men's health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer. American Journal of Clinical Nutrition, 2016, 104, 1583-1593.	4.7	2
143	Exceptional Responders in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 624-635.	1.3	2
144	Salvage therapy at biochemical recurrence of prostate cancer. Nature Reviews Urology, 2020, 17, 195-196.	3.8	2

#	Article	IF	CITATIONS
145	Image-Guided Focused Ultrasound for the Treatment of Bone Metastases: Current Status and Future Direction. Current Radiology Reports, 2013, 1, 147-153.	1.4	1
146	Dosimetric and Clinical Predictors of Long-Term Toxicity in Patients Undergoing Hypofractionated Prostate Radiation Therapy: Results From a Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, S123.	0.8	1
147	Deviations From Standard Chemoradiation Among Early-Stage Anal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 100, 945-949.	0.8	1
148	Long-Term Causes of Death Among Pediatric Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, E16-E17.	0.8	1
149	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319–28. European Urology, 2019, 75, e96-e97.	1.9	1
150	Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options. Frontiers in Oncology, 2020, 10, 1616.	2.8	1
151	Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted". Annals of Translational Medicine, 2015, 3, 274.	1.7	1
152	Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes. Clinical Genitourinary Cancer, 2022, , .	1.9	1
153	Demystifying radiation oncology clinical trial concerns for protocol scientific review and institutional review board committee members. Contemporary Clinical Trials Communications, 2022, 27, 100911.	1.1	1
154	Oncology training programs: are we doing comparative effectiveness research justice?. Journal of Comparative Effectiveness Research, 2013, 2, 573-582.	1.4	0
155	Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. Journal of Thoracic Disease, 2016, 8, E1028-E1031.	1.4	0
156	970: Overtreatment of patients with clinically diagnosed early stage lung cancer. Journal of Thoracic Oncology, 2016, 11, S99.	1.1	0
157	Pretreatment Predictors of Receiving Adjuvant Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E280.	0.8	0
158	Applying ASTRO APEx Guidelines and RO-ILS to Medical Malpractice in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2016, 96, E540.	0.8	0
159	Postmastectomy Radiation Therapy in Women With ypNO-N3 Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E27.	0.8	0
160	Brachytherapy for Prostate Cancer: An Overview. , 2016, , 399-411.		0
161	(P088) Splenic Irradiation for Splenomegaly: A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 98, E39.	0.8	0
162	(P094) Financial Conflicts of Interest Are Correlated With Publication Productivity Among Academic Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2017, 98, E40-E41.	0.8	0

#	Article	IF	Citations
163	(P077) Hypofractionated Radiation Therapy has Favorable Cosmesis for Indolent Skin Cancers. International Journal of Radiation Oncology Biology Physics, 2017, 98, E36.	0.8	0
164	(P034) Evolution of Brachytherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, E24.	0.8	0
165	Toxicity After Radiotherapy in Patients with Historically Accepted Contraindications to Treatment (CONTRAD): An International Systematic Review and Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2019, 103, E20.	0.8	0
166	The Decline in Brachytherapy Use for Definitive Cancer Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, E45-E46.	0.8	0
167	Surgical Excision, Mohs Micrographic Surgery, External Beam Radiotherapy, or Brachytherapy for Indolent Skin Cancer: An International Meta-analysis of 58 Studies with 21,000 Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, E34-E35.	0.8	0
168	Ablative Stereotactic Radiation Therapy for Oligo-metastatic Cancer (ARCHON): An International Meta-analysis of 19 Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2019, 103, E5-E6.	0.8	0
169	Prostate and Pelvis on Pause Pending a Pandemic. International Journal of Radiation Oncology Biology Physics, 2020, 108, 341-342.	0.8	0
170	Authors' Reply: To the Letter to the Editor by Kessel et al. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, xliii-xliv.	4.9	0
171	Potential Winners and Losers: Understanding How the Oncology Care Model May Differentially Affect Hospitals. JCO Oncology Practice, 2021, 17, e1150-e1161.	2.9	0
172	Exercise: A Treatment That Should Be Prescribed With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	0
173	Assessment of the American Joint Committee on Cancer (6th and 7th editions) for clinically localized prostate cancer and comparison to the National Comprehensive Cancer Network risk stratification method Journal of Clinical Oncology, 2012, 30, 23-23.	1.6	0
174	SU-E-T-598: Variability of Computer-Generated Organ at Risk Contours as Part of An Automated Deformable Registration Workflow for Prostate Cancer. Medical Physics, 2013, 40, 343-343.	3.0	0
175	Genitourinary Cancers., 2019,, 313-359.		0
176	Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma. Journal of Thoracic Disease, 2020, 12, 6476-6493.	1.4	0
177	Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma. Journal of Thoracic Disease, 2020, 12, 6476-6493.	1.4	0